Navigation Links
Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
Date:10/10/2007

SYDNEY, Australia, Oct. 10 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it had raised A$50 million through a placement to Australian, U.S., Asian and European institutions and professional investors. The placement strengthens the company's balance sheet as Pharmaxis continues with a series of international Phase III trials and embarks on the expansion of its manufacturing operation in Sydney.

Pharmaxis will issue 12.8 million new fully paid ordinary shares at A$3.90 per share, an 8.9% discount to Pharmaxis' last closing price on 8 October and a 2.0% discount to the volume weighted average share price over the past 30 days. The shares to be issued will rank equally with existing ordinary shares in the capital of the company. Shares sold to U.S. institutions have not been registered under the Securities Act of 1933 and were placed under an exemption from the Act.

Settlement of the placement is scheduled to take place on 16 October 2007.

A share purchase plan will be offered to all Australian and New Zealand shareholders who hold shares as at 7.00pm on 11 October 2007 and will afford the opportunity to purchase up to $5,000 worth of fully paid ordinary shares at the placement price of A$3.90, without brokerage or transaction costs. The share purchase plan offer opens on 19 October and closes on 09 November 2007.

CONTACT:

Alan Robertson - Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Virginia Nicholls

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

About Pharmaxis

Pharmaxis (A
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...Newswire-FirstCall/ -- BioForm Medical,Inc. (Nasd...for the fourth,quarter and full fiscal year ended ...e quarter ended June 30, 2008 as compared to $15.4...ncrease of $1.3 million or 8.4%.,The net loss was ...as,compared to a net loss of $4.9 million for the ...
(Date:9/4/2008)... 4 /-, - Prevenar Vaccine ...ne-Preventable Cause of Death in Young Children Wo...e Republic of Ireland have,initiated national immu...hildren against pneumococcal disease by adding Pre...ine, Adsorbed), also called PCV7, to their,nationa...
(Date:9/4/2008)...niversity of North Carolina-Chapel Hill Anno...ces, RESEARCH TRIANGLE PARK, N.C., Sept. 4 /PRNew...s and the University of North Carolina at,Chapel H... for Drug Safety,Sciences that will be led by Dr. ...n drug-induced liver injury. As founding director ...
(Date:9/4/2008)...Commercialization of Recently FDA-cleared ...YVALE, Calif., Sept. 4 /- Pathwork Di... on oncology, announced the closing,today of a $20...ment came,on the heels of FDA,s clearance for the ... tumors of uncertain origin, including poorly,diff...
Breaking Biology Technology:BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 2BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 3BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 4BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 5BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 6BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 7BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 8BioForm Reports Financial Results for the Fourth Quarter and Full Fiscal Year Ended June 30, 2008 9Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules 2Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules 3New Hamner-UNC Center for Drug Safety Sciences 2New Hamner-UNC Center for Drug Safety Sciences 3Pathwork Diagnostics Closes $20M Financing 2
...ad Part 1 . Winslow Sargeants combination of acad...im rare insight into the world of entrepreneurship...r remind him that to succeed at anything, tenacity...far removed from the place Sargeant knew as a chil...hur Garrity, Jr. ordered massive busing throughout...
...16 percent the past two years, Wisconsin,s bioscie...ically known for beer, brats, and milk, says Gale ...released today at the State Capitol in Madison. ,...ing that fast?" she asked. Davy is the executive d...al Research & Education , a non-profit group spons...
...Wisconsin company specializing in functional Magne..., announced today that the Food and Drug Administr...arket clearance of its trademarked MindState fDAD.... in February 2005 as an fMRI data acquisition devi...ance fDAD by providing a library of stimulation pa...
...ectorConnector , that connects businesses and non-...is up to 500 registered users, according to the tw...hael Best & Friedrich, LLP and the accounting fi...to connect organizations in need of specially-skil...idates. Recent surveys indicate that directors are...
Other Biology Technology:Winslow Sargeant: Stepping onto the train called Wisconsin - Part 2 2Winslow Sargeant: Stepping onto the train called Wisconsin - Part 2 3Winslow Sargeant: Stepping onto the train called Wisconsin - Part 2 4Bioscience beats beer 2
(Date:9/3/2008)...lm Vein Recognition Solution Named the Winner in t...ealthcare Category, SUNNYVALE, Calif., Sept. 3 /P..., Inc., a leading supplier of innovative computer ...nd biometric security solutions, announced,today t...on was named the,winner in the Best Security Solut...
(Date:9/3/2008)...NNE, Ill. (Sept. 3, 2008) Scientists at the U.S. ...ratory have won an $800,000 EUREKA award from the ...MAX, a precise molecular ruler for measuring dista...for the Multi-wavelength Anomalous Diffraction usi...ot only dramatically reduce the time necessary to ...
(Date:9/3/2008)...FAX, Va.Ten million Americans have peripheral arte...ghest risk populations include African-Americans (...seniors (12-20 percent develop PAD) and diabetics ...AD). Legs for Lifea community health and public in...ake its free, online self-assessment quiz. , The...
(Date:9/3/2008)...ation in the gene for one of the receptors for the... how human males bond with their partners, accordi...The researchers found that the "334" allele of a c...a studied in voles, seemed to have negative effect...Our findings are particularly interesting because ...
Breaking Biology News(10 mins):Fujitsu PalmSecure(TM) Wins Network Products Guide 2008 Reader Trust Award 2Fujitsu PalmSecure(TM) Wins Network Products Guide 2008 Reader Trust Award 3NIH awards Argonne $800,000 to develop tool to measure distances within proteins 2At risk for peripheral arterial disease? Simple quiz provides key so you can circulate better 2At risk for peripheral arterial disease? Simple quiz provides key so you can circulate better 3Gene associated with pair-bonding in animals has similar effects in human males 2Gene associated with pair-bonding in animals has similar effects in human males 3Celldex Therapeutics Receives Fast Track Designation for CDX 110 a Novel EGFRvIII Vaccine for Glioblastoma 1143 1Celldex Therapeutics Receives Fast Track Designation for CDX 110 a Novel EGFRvIII Vaccine for Glioblastoma 1143 2Celldex Therapeutics Receives Fast Track Designation for CDX 110 a Novel EGFRvIII Vaccine for Glioblastoma 1143 3Celldex Therapeutics Receives Fast Track Designation for CDX 110 a Novel EGFRvIII Vaccine for Glioblastoma 1143 4Celldex Therapeutics Receives Fast Track Designation for CDX 110 a Novel EGFRvIII Vaccine for Glioblastoma 1143 5Difficult to Treat Erectile Dysfunction Patients 2474 1Difficult to Treat Erectile Dysfunction Patients 2474 2Difficult to Treat Erectile Dysfunction Patients 2474 3A special issue of the International Journal of Plant Sciences 1788 1A special issue of the International Journal of Plant Sciences 1788 2A special issue of the International Journal of Plant Sciences 1788 3UCLA scientists restore walking after spinal cord injury 9123 1UCLA scientists restore walking after spinal cord injury 9123 2UCLA scientists restore walking after spinal cord injury 9123 3
... family,s ancestors roamed 60,000 years ago? ,Now ...ost ambitious project tracing the genetic and migr...general public from all over the world can supply ...ts at The University of Arizona in Tucson will do ...art of a larger undertaking to unravel the origins...
...ter it burst onto the scene, HIV/AIDS has claimed ...vastate societies around the world, particularly i...te 1980s and early 1990s, after years of effort AI...drugs that proved to be highly effective against A...HIV protease, these protease inhibitors brought gr...
...ffensive strategies can become weaknesses, if the ...its weapons. , By manipulating what is perhaps th...ox viruses like smallpox, Arizona State University...tram Jacobs believes that he can turn the biochemi...s ?and protect the public against catastrophic bio...
...l University Health Centre (MUHC), in Montreal, ha...w study, published in the on-line edition of the j...earchers document a reduction in the growth of bot...the gene. , The new target gene is called methylen... were able to inhibit the function of the gene by ...
Other Biology News:The biggest family tree ever 2The biggest family tree ever 3Supercomputers to focus brains on AIDS dilemma 2Supercomputers to focus brains on AIDS dilemma 3Supercomputers to focus brains on AIDS dilemma 4Secret of smallpox's success may lead to bioterror cure 2Secret of smallpox's success may lead to bioterror cure 3Secret of smallpox's success may lead to bioterror cure 4Secret of smallpox's success may lead to bioterror cure 5
A high quality source of amino acids and peptides produced by the enzymatic digestion of casein. It is recommended for laboratory media and fermentations and has been used in antibiotics, toxins and
QIAshredder (50) from QIAGEN
...n Ham's F12K medium with 2 mM L-glutamine and harv... the antigens in their native forms, cells were fi...a 12-well (5 mm) adhesive coated slide, with each ...ular attachment and to minimize background stainin...
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)
Biology Products: